Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Indoximod

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Indoximod: Sponsors, patents, clinical trial progress

Indoximod is an investigational drug.

There have been 14 clinical trials for Indoximod. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2017.

The most common disease conditions in clinical trials are Brain Neoplasms, Glioma, and Glioblastoma. The leading clinical trial sponsors are NewLink Genetics Corporation, National Cancer Institute (NCI), and Emory University.

There are fifty-six US patents protecting this investigational drug and four hundred and thirty-five international patents.

Recent Clinical Trials for Indoximod
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPGEmory UniversityPhase 2
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPGTheodore S. JohnsonPhase 2
A 2-part, Phase 1, Randomized Study in Health Men to: 1) Evaluate the Pharmacokinetics and Safety of Different Doses Indoximod HCL (Salt) Tablets and; 2) Compare the Proportion of 2 Different Formulations of Indoximod That Enters the Circulation andNewLink Genetics CorporationEarly Phase 1

See all Indoximod clinical trials

Clinical Trial Summary for Indoximod

Top disease conditions for Indoximod
Top clinical trial sponsors for Indoximod

See all Indoximod clinical trials

US Patents for Indoximod

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Indoximod   See Pricing Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   See Pricing
Indoximod   See Pricing Antibodies to ICOS Jounce Therapeutics, Inc. (Cambridge, MA)   See Pricing
Indoximod   See Pricing Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.